Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. QUIA PHARMA AB's Total Liabilities for the quarter that ended in Jun. 2025 was €0.80 Mil. QUIA PHARMA AB's Total Assets for the quarter that ended in Jun. 2025 was €1.39 Mil.
Therefore, QUIA PHARMA AB's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2025 was 0.58.
QUIA PHARMA AB (FRA:99B0) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
QUIA PHARMA AB Liabilities-to-Assets Related Terms
QUIA PHARMA AB Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for QUIA PHARMA AB's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:99B0 vs VRTX, REGN, ALNY: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, QUIA PHARMA AB's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QUIA PHARMA AB Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where QUIA PHARMA AB's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
QUIA PHARMA AB's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
QUIA PHARMA AB (FRA:99B0) has a Liabilities-to-Assets of 0.58 as of Jun. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's Liabilities-to-Assets too high?
QUIA PHARMA AB's current Liabilities-to-Assets is 0.58.
How does QUIA PHARMA AB's Liabilities-to-Assets compare to VRTX and REGN?
QUIA PHARMA AB's Liabilities-to-Assets of 0.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on QUIA PHARMA AB and its competitors. QUIA PHARMA AB's current Liabilities-to-Assets is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current Liabilities-to-Assets of 0.58. The current Liabilities-to-Assets is 0.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current Liabilities-to-Assets is 0.58 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:99B0 has been successfully added to your 
